Abstract
Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.
| Original language | English |
|---|---|
| Journal | Clinical Neuropharmacology |
| Volume | 12 |
| Issue number | SUPPL. 2 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Pharmacology (medical)
- Neuroscience(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Pharmacology of amineptine : Synthesis and updating. / Garattini, S.; Mennini, T.
In: Clinical Neuropharmacology, Vol. 12, No. SUPPL. 2, 1989.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacology of amineptine
T2 - Synthesis and updating
AU - Garattini, S.
AU - Mennini, T.
PY - 1989
Y1 - 1989
N2 - Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.
AB - Amineptine is a tricyclic antidepressant agent with the unique capacity to decrease selectively the uptake of dopamine (DA) without affecting the uptake of noradrenaline (NA) and serotonin (5HT). The effect is obtained both in vitro and in vivo by the use of suitable methodology. Amineptine can be differentiated from amphetamine both on the basis of pharmacological as well as biochemical parameters. In vivo, amineptine increases striatal homovanillic acid without affecting the levels of other metabolites of DA, namely, 3, 4, dihydrozoxyphenylacetic acid (DOPAC) and 3-methoxytramine (3MT). However, by using relatively high doses of amineptine, the extracellular DOPAC level - assessed by the use of pulse voltammetry - was decreased preferentially in the nucleus accumbens but not in the striatum. Chronic treatment with amineptine, as with other antidepressant agents, induces a down-regulation of β-adrenergic receptors. Amineptine enters the brain and its pharmacological effects are likely due to the unchanged drug rather than to its two main metabolites.
UR - http://www.scopus.com/inward/record.url?scp=0024946958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024946958&partnerID=8YFLogxK
M3 - Article
C2 - 2698268
AN - SCOPUS:0024946958
VL - 12
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
SN - 0362-5664
IS - SUPPL. 2
ER -